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Abstract
Background: Aberrant expression of long noncoding RNAs (lncRNAs) has frequently been reported in cancer studies,
including those of colorectal cancer (CRC). Increasing evidence suggests that lncRNAs are significantly correlated with
the pathogenesis, development and metastasis of cancer. Loc554202 is a 2166-bp transcript on human chromosome
9p21.3, the expression of which is dysregulated in breast and lung cancer cells. However, its role in CRC remains under
investigation.
Methods: Quantitative real-time polymerase chain reaction (qRT-PCR) was carried out to assess the relative expression
of Loc554202 in CRC cell lines and tissues. Gain and/or loss of function approaches were used to investigate the
potential functional roles in cell proliferation and apoptosis in vitro and in vivo. qRT-PCR, western-blotting and
immunohistochemistry were used to evaluate the mRNA and protein expression of apoptosis-related factors.
Results: Loc554202 was significantly downregulated in cancerous tissues and CRC cell lines compared with adjacent
normal tissue and a normal human intestinal epithelial cell line. Low Loc554202 expression was closely associated with
advanced pathologic stage and a larger tumor size. The overexpression of Loc554202 decreased the cell proliferation
and induced apoptosis in vitro and hindered tumorigenesis in vivo. Loc554202 regulated cell apoptosis partly through
the activation of specific caspase cleavage cascades.
Conclusion: Our results suggest that Loc554202 may play an important role in the progression of CRC and could be a
candidate prognostic biomarker or a target for new cancer therapies.
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Introduction
Colorectal cancer (CRC), as the third most common cancer
affecting the gastrointestinal tract, is a common type of
cancer worldwide, and is associated with a high mortality
rate due to its rapid progression and advanced tumor pres-
entation at the time of diagnosis [1–3]. CRC is becoming
more prevalent in China [4]. The vast majority of CRC
patients have reached an advanced pathological stage before
symptoms appear; therefore, that the survival rate of those
diagnosed with CRC remains poor. The early detection of
CRC is significantly beneficial to improve the probability of
survival. Therefore, a better understanding of the mecha-
nisms that result in CRC and the identification of a new
molecular marker or factor that can be used to create novel
diagnostic and therapeutic strategies is urgently needed for
patients with CRC.
Long non-coding RNAs (lncRNAs, > 200 nucleotides in
length) are a class of newly discovered non-coding RNA
molecules with limited or no protein-coding capacity [5, 6].
Recently, increasing evidence has shown that lncRNAs have
important biological functions are closely related to human
diseases, especially cancer [7–10]. They may function as
oncogenes [11, 12] or anti-oncogenes [13, 14] similar to
protein-coding genes, and their dysregulated expression is
significantly correlated with carcinogenesis [15]; therefore,
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they may be considered to be promising candidate bio-
markers for diagnosing cancer and may also represent
therapeutic target in the future.
The underlying molecular mechanisms by which
lncRNAs exert their functions are complex, diverse and
exist at various levels during the development of cancer, in-
cluding the epigenetic, transcriptional, post-transcriptional
and translational levels [16–18]. For instance, lncRNA
HOTAIR is upregulated in CRC and may be a critical elem-
ent in metastatic progression as a result of its interaction
with PRC2 (Polycomb Repressive Complex 2) [19]. Our
previous studies also showed that HOTAIR could function
as a competing endogenous RNA to regulate HER2 expres-
sion by sponging miR-331-3p in gastric cancer [20];
lncRNA SPRY4-IT1 could be a growth regulator, and pro-
moted the proliferation of ER (−) human breast cancer cells
by upregulating the expression of ZNF703 [21].
Loc554202, is a 2166-bp transcript on human chromo-
some 9p21.3, which is the host gene of miR-31 and dysreg-
ulated in breast [22, 23] and lung [24] cancer cells,
although the importance of its function has not yet been
established. Little is known concerning the potential role of
Loc554202 in the development and progression of CRC.
To detect the functions and molecular mechanisms of
Loc554202 in CRC, we conducted a qRT-PCR analysis of
Loc554202 expression in human CRC tissues and cell lines,
and showed that the expression of Loc554202 was signifi-
cantly downregulated in cancerous tissue samples and CRC
cell lines compared with matched normal samples. Its
downregulation was closely associated with an advanced
pathological stage and a large tumor size. Further func-
tional studies of Loc554202 indicated that enhanced
expression of Loc554202 could decrease cell proliferation
and induce apoptosis in vitro and in vivo.
Materials and methods
Tissue collection
Colorectal cancer tissues and normal tissues were ob-
tained from 48 patients who had undergone surgical
resection of colorectal cancer between 2010 and 2012 at
Second Affiliated Hospital of Nanjing Medical, China. No
local or systemic treatment had been administered to
these patients prior to the operation. All tissue samples
were washed with sterile phosphate-buffered saline before
being snap frozen in liquid nitrogen and then stored
at −80 °C until required for the analyses. The pathological
stage, grade and nodal status were appraised by an experi-
enced pathologist. The clinicopathological characteristics,
including the tumor, node metastasis (TNM) staging are
summarized in Table 1. The non-tumorous tissues were
5 cm from the edge of the tumor, and there were no obvi-
ous tumor cells present in these regions as determined by
the pathologist. All of the experiments were approved by
the Research Ethics Committee of Nanjing Medical
University, China. Written informed consent was
obtained from all patients.
Ethics statement
The study was approved by the Ethics Committee of
Nanjing Medical University and was performed in compli-
ance with the Declaration of Helsinki. Written informed
consent was obtained for the use of all patient samples.
All experimental animals were housed under specific
pathogen-free conditions. All experimental procedures
were approved by the Institutional Review Board of Nan-
jing Medical University. All procedures were performed in
accordance with the Nanjing Medical University Guide for
the Care and Use of Laboratory Animals which was for-
mulated by the National Society for Medical Research.
Cell lines and culture conditions
The human colorectal cancer cell lines (HCT116, DLD1,
SW480, RKO, HT-29) were purchased from the Institute
of Biochemistry and Cell Biology of the Chinese Acad-
emy of Sciences (Shanghai, China). The human colonic
epithelial cells HCoEpiC were obtained from American
Type Culture Collection (Manassas, VA). They were cul-
tured in Dulbecco’s modified Eagle’s medium (DMEM;
Invitrogen) in humidified air at 37 °C with 5 % CO2. All
media were supplemented with 10 % fetal bovine serum
(10 % FBS), 100 U/ml penicillin, and 100 mg/ml strepto-
mycin (Invitrogen, Shanghai, China).
RNA extraction and qRT-PCR analyses
Total RNA was extracted from tissues or cultured
cells with the TRIZOL reagent (Invitrogen Life
Technologies) according to the manufacturer’s proto-
cols. For qRT-PCR, RNA reverse transcribed to
cDNA from 1 μg of total RNA was reverse tran-
scribed in a final volume of 20 μl using random
primers and a Reverse Transcription Kit (Takara,
Dalian, China). According to the manufacturer’s in-
structions, the reverse transcription was performed
at 37 °C for 15 min, then at 85 °C for 5 s. qRT-PCR
analyses were performed using a standard protocol
from Power SYBR Green (Takara, Dalian, China). All
protocols were performed according to the manufac-
turer’s instructions. The Δct values were normalized
to those of glyceraldehyde-3-phosphate dehydrogen-
ase (GAPDH). The primer sequences used for the
studies are shown in Additional file 1: Table S1. The
qRT-PCR assays and data collection were performed
using an ABI 7500 instrument. Each sample was an-
alyzed in triplicate.
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Treatment of HCT116 and DLD1 cells with 5-aza-2-deoxy-
cytidine (5-aza-CdR)
CRC cells (2.5 × 105) were seeded into six-well culture-
plates and exposed to 0, 5 or 10 μM 5-aza-CdR (Sigma-Al-
drich, USA). Cells were harvested after 72 h for qRT-PCR
to detect the expression level of Loc554202.
Transfection of colorectal cancer cells
Small interfering RNA (siRNA) and nonspecific control
siRNA were synthesized (Carlsbad, California, USA) and
transfected into cells using Lipofectamine 2000 (Invitro-
gen, USA). To overexpress Loc554202, the full length cod-
ing sequence for Loc554202 was amplified and subcloned
into the pcDNA 3.1(+) vector (Invitrogen) according to
the manufacturer’s instructions. HCT116 and DLD1 cells
were transfected with a negative control vector or the
Loc554202-expressing plasmid according to the manufac-
turer’s protocol. Cells were harvested after 48 h for qRT-
PCR and western blot analyses. The sequences of the
siRNAs are described in Additional file 2: Table S2.
Cell proliferation assays
Forty-eight hours after pCDNA-Loc554202 transfection,
3,000 cells per well were allowed to grow in 96-well plates
with five replicate wells. After 6 h of culture, as well as at
24, 48, 72 and 96 h after atarting the culture, the cells were
treated with 100 μg 3-(4,5-dimethylthiazol-2-yl)-2,5-diphe-
nyltetrazolium bromide (MTT) by adding it to the medium.
The cells were incubated at 37 °C for another 4 h, then the
medium was removed, and dimethylsulfoxide (DMSO) was
added for 10 min to lyse the cells. Finally, the absorbance
was measured at 490 nm. All experiments were performed
in triplicate.
Colony formation and clonogenic assays
Cells were trypsinized into single-cell suspensions 48 h after
transfection. For the colony formation assay, 1,000 cells
were plated into each well of a six-well plate and were
maintained in media containing 10 % FBS to allow colony
formation, with the medium being repalaced every four
days. After two weeks, colonies were fixed with methanol
and stained with 0.1 % crystal violet (Sigma) in PBS for
15 min. The visible colonies were manually counted. Tripli-
cate wells were measured for each treatment group.
Flow cytometry
Cells transiently transfected with pCDNA-Loc554202 were
harvested 48 h after transfection by trypsinization, washed
with ice-cold phosphate-buffered saline, and fixed with
75 % ethanol overnight. The cells used for the cell-cycle
analysis were stained with propidium oxide (100 μg/mL)
using the Cycle Test Plus DNA Reagent Kit (BD Biosci-
ences) and were analyzed by flow cytometry (FACScan;BD
Biosciences) using an instrument equipped with the Cell-
Quest software program (BD Biosciences). The percentages
of cells in the G0–G1, S, and G2–M phases were counted
and compared. The cells used for the apoptosis analysis
were harvested 48 h after transfection, and were stained for
15 min with fluorescein isothio-cyanate (FITC)-Annexin V
and propidium iodide (PI) in the dark at room temperature,
according to the manufacturer’s recommendations. The
cells were then examined by flow cytometry (FACScan; BD
Biosciences) and the CellQuest software program (BD
Biosciences) and were discriminated into viable cells, dead
cells, early apoptotic cells, and apoptotic cells. The percent-
age of early apoptotic cells was compared with the control
groups from each experiment.
All of the samples were assayed in triplicate.
TUNEL
Terminal deoxynucleotidyl transferase-mediated dUTP
nick end labeling (TUNEL) was performed with an apop-
tosis detection kit (KeyGEN BioTECH, China) according to
the manufacturer’s instructions. Randomly selected fields
without significant necrosis in 10 high-power fields (6400)
Table 1 Correlation between Loc554202 expression and
clinicopathological characteristics of CRC patients
Characteristics Number Percent Loc554202 p
(n = 48) High Low Chi-squared
test P-value
Age (years) 0.560
<60 21 43.8 % 11 10
≥60 27 56.2 13 14
Gende 0.430
Male 29 60.4 % 15 14




<5 cm 28 58.3 % 19 9
≥5 cm 20 41.7 % 5 15
Location 0.440
Colon 19 39.6 % 10 9




T1 and T2 18 37.5 % 11 7
T3 and T4 30 62.5 % 13 17
Tumor stage 0.028*
I and II 26 54.2 % 17 9




Negative 25 52.1 % 12 13
Positive 23 47.9 % 12 11
* P<0.05 was considered significant (Chi-square test between two groups)
Ding et al. Journal of Experimental & Clinical Cancer Research  (2015) 34:100 Page 3 of 11
were assessed for TUNEL-positive cells. The TUNEL index
was calculated based on the number of total nuclei and the
number of cells with green nuclei.
Western blot analysis and antibodies
Cells were lysed using the mammalian protein extraction
reagent, RIPA (Beyotime), supplemented with a protease
inhibitor cocktail (Roche) and PMSF (Roche). Protein
were separated by 10 % sodium dodecyl sulfate–poly-
acrylamide gel electrophoresis (SDS–PAGE) and trans-
ferred to 0.22 mm nitrocellulose (NC) or polyvinylidene
difluoride membranes (Sigma). The membranes were
washed, blocked, and incubated with specific primary anti-
human antibodies. The secondary antibody was horserad-
ish peroxidase-conjugated goat anti-rabbit IgG. An ECL
chromogenic substrate was used to visualize the bands
and the intensity of the bands was quantified by densitom-
etry (Quantity One software; Bio-Rad). The mean ± SD
values were calculated from three individual experiments.
A GAPDH antibody was used as a control, and the anti-
cleaved caspase-3, cleaved caspase-9, Bcl-2 and Bax (all
1:1000) antibodies were purchased from Cell Signaling
Technology, Inc. (CST).
Tumor formation assay in a nude mouse model
Four-week-old male BALB/c nude mice were obtained
from the Shanghai Laboratory Animals Center of the
Chinese Academy of Sciences (Shanghai, China). The mice
were housed under pathogen-free conditions with a 12 h
light/dark schedule, were fed an autoclaved diet ad libitum,
and were injected subcutaneously with 5 × 106 cells to as-
sess the tumor formation. Tumor growth was examined
every three days, and tumor volumes were calculated using
the following formula: 0.5 × length ×width2. At two weeks
after the cell injection, the mice were killed, and the sub-
cutaneous weight of each tumor was measured and the tu-
mors were used for further analyse. The protocol was
approved by the Committee on the Ethics of Animal Exper-
iments of the Nanjing Medical University.
Immunohistochemical (IHC) analysis
Tumor tissue samples were immunostained for cleaved
caspase-3 as described previously. The expression was
considered to be positive when 50 % or more cancer cells
were stained. The anti-cleaved caspase-3(1:50) antibody
was purchased from CST.
Statistical analysis
All data were expressed as the means ± SD (standard devi-
ation, SD), and were analyzed using Student’s t test between
to compare two groups of in vitro and in vivo data using
the SPSS 17.0 software program. A value of P < 0.05 was
considered to be statistically significant.
Results
Loc554202 expression is downregulated in human
colorectal cancer tissues and colorectal cancer cell lines
We first examined the Loc554202 expression levels in 48
colorectal cancer tissue samples and 48 matched normal
colorectal tissue samples by performing a qRT-PCR
analysis. The Loc554202 expression was downregulated
(P < 0.05) in the cancerous tissues compared with the cor-
responding adjacent non-tumorous tissues (Fig. 1a). To
further understand the significance of Loc554202 expres-
sion in CRC, we then evaluated the correlation of
Loc554202 expression with various clinicopathological
features (i.e., stage, maximum diameter) (Table 1). As
shown in Fig. 1b and c, low Loc554202 expression in CRC
was significantly correlated with the tumor size (p = 0.003)
and advanced TNM stage (p = 0.020), which reflect a
higher tumor burden. However, Loc554202 expression
was not associated with other parameters such as age
(p = 0.146) or gender (p = 0.768) in CRC patients (Table 1).
These results imply that Loc554202 may be a potential
prognostic biomarker for CRC patients.
We next examined the expression of Loc554202 in five
human colorectal cancer cell lines (HT-29, SW480,
RKO, HCT116, and DLD1) and a normal colonic epithe-
lial cell (HCoEpiC). Figure 1d shows that the Loc554202
expression levels were indeed lower in all of the CRC
cell lines examined compared with the normal intestinal
epithelial cells (p < 0.01). We chose to use the HCT116
and DLD1 cell lines for further studies because they had
the lowest expression levels. Furthermore, to detect the
transfection efficiency and eliminate the influence of
miR-31 may exist on overexpression of Loc554202, the
expression levels of Loc554202 and miR-31 were
detected by a qRT-PCR analysis after transfecting these
cells with pCDNA-Loc554202. The results found that
the Loc554202 expression was increased by 47.5-fold
and 38-fold in the HCT116 and DLD1 cells, respectively,
compared with the control cells following transfection with
pCDNA-Loc554202 (Fig. 1e), and there was no significant
change in miR-31 expression (Additional file 3: Figure S1).
Effects of DNA methylation on the Loc554202 expression
in colorectal cancer cells
Although the hypermethylation of Loc554202 has been
reported to be involved in its transcriptional inactivation in
breast cancer, whether this is also the case in CRC was
unknown. To determin the influence of DNA methylation
in CRC cells, we treated HCT116 and DLD1 cells with a
DNA demethylating agent (5-aza-CdR) for 72 h, and found
that the Loc554202 expression was significantly increased
by 1.9- or 4.2- fold, or by 1.4- or 3.1- fold in the 5-aza-CdR-
treated HCT116 (Fig. 1f) and DLD1 (Fig. 1g) cells, respect-
ively, compared with the control cells.
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Overexpression of LOC554202 inhibits colorectal cancer
cell proliferation in vitro
To investigate the potential biological function of
Loc554202 in CRC cells, the MTT assay was performed
to detect the impact of Loc554202 overexpression on
the proliferation of HCT116 and DLD1 colorectal cancer
cells. The results showed that the growth of HCT116
and DLD1 cells transfected with pCDNA-Loc554202
was significantly inhibited compared with that of con-
trol cells (p < 0.05; Fig. 2a). Similarly, colony forma-
tion assays were performed to reveal the long-term
anti-proliferative effects of Loc554202 on the growth
of HCT116 and DLD1 cells. These data suggest that
the colony numbers of colorectal cancer cells trans-
fected with pCDNA-Loc554202 were obviously lower
than those of the negative control cells (p < 0.05;
Fig. 2b). These findings indicate that Loc554202 may
act as a tumor suppressor, and may inhibit CRC cell
proliferation.
Overexpression of Loc554202 promotes G1 arrest and
causes apoptosis in colorectal cancer cells in vitro
To further assess whether the anti-proliferative effects of
Loc554202 on the CRC cells were mediated by inhibiting
cell cycle progression, we examined the cell cycling in
HCT116 and DLD1 cells by flow cytometry. The results
demonstrated that Loc554202 overexpression promoted a
significant arrest of both cell lines in the G0/G1-
phase (p < 0.05), with an obvious reduction in the
number of cells in the S-phase (p < 0.05; Fig. 3a and b).
In addition, to investigate whether apoptosis regula-
tion was potential contributing factor to the cell
growth inhibition induced by Loc554202, an apoptosis
assay was performed using flow cytometric analysis.
Fig. 1 Relative expression of Loc554202 in colorectal cancer tissues and cells compared with adjacent normal tissues and normal colonic epithelial cells.
a The relative expression of Loc554202 in colorectal cancer tissues (n= 48) compared with corresponding non-tumor tissues (n= 48). The Loc554202
expression was examined by qRT-PCR and was normalized to the GAPDH expression. The results are presented as the fold-change in tumor tissues
relative to normal tissues (shown as -ΔΔCT). b and c) The data are presented as the relative expression levels in tumor tissues. The Loc554202 expression
was significantly lower in patients with a higher pathological stage and larger tumors. d The Loc554202 expression was assessed by qRT-PCR in colorectal
cancer cell lines (HT-29, RKO, SW480, HCT116, DLD1) and was compared with the normal human colonic epithelial cell line (HCoEpiC). e The relative
expression levels of Loc554202 following the treatment of HCT116 and DLD1 cells with pCDNA-Loc554202 and empty vector. (f and g) The level of
Loc554202 expression in HCT116 and DLD1 cells following treatment with 5-aza-dC (0, 5, 10 μM).* P< 0.05 and ** P< 0.01
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As shown in Fig. 3c and d, the proportions of apoptotic
cells following pCDNA-Loc554202 treatment were signifi-
cantly increased compared with those in the control group
(p < 0.05). Moreover, a microscopic analysis of TUNEL
staining in HCT116 and DLD1 cells confirmed these find-
ings (Fig. 3e). Taken together, these data indicate that
Loc554202 treatment could arrest cells in the G0/G1-phase
of the cell cycle and induce apoptosis in CRC cells. These
data suggest that Loc554202 exerts critical effects on CRC
cells by affecting both the cell cycle and apoptosis.
Knockdown of Loc554202 mildly promotes the
proliferation of HCT116 and DLD1 cells in vitro
To verify that the Loc554202 expression was inversely
related to colorectal cancer progression, we used siRNAs to
downregulate the endogenous Loc554202 expression in the
HCT116 and DLD1 cell lines. MTT assays and colony for-
mation assays were performed as described previously, and
we found that the siRNA transfection-mediated Loc554202
knockdown increased the cell growth compared with nega-
tive control cells in both cell lines. The cell viabilities of
both cell lines following treatment with the Loc554202
siRNA were moderately higher than that in the control
group (p < 0.05; Fig. 4a). The results of the colonyformation
assay showed that the clonogenic survival was increased
when Loc554202 was downregulated in the HCT116 and
DLD1 cell lines (p < 0.05; Fig. 4b). These observations
indicated that low Loc554202 expression may contribute to
CRC progression.
Overexpression of Loc554202 inhibits CRC tumorigenesis
in vivo
To determine whether the overexpression of Loc554202
could affect tumorigenesis, pCDNA-Loc554202 and empty
vector transfected HCT116 cells were inoculated into male
nude mice. Fifteen days after inoculation, all mice devel-
oped xenograft tumors at the injection site. However, the
tumors formed in the pCDNA-Loc554202 group were dra-
matically smaller than those in the empty vector group
(Fig. 5a). Remarkably, the average tumor weight was obvi-
ously lower in the pCDNA-Loc554202 group compared
with the empty vector group (Fig. 5b). Consistently, the
tumor growth in the pCDNA-Loc554202 group was signifi-
cantly slower than that in the control group (Fig. 5c). A
qRT-PCR analysis of the Loc554202 expression was then
performed using the xenograft tumor tissues. The results
showed that the levels of Loc554202 expression in tumor
tissues formed from pCDNA-Loc554202 cells were lower
than those of the tumors formed in the control group
(p < 0.05, Fig. 5d). We also examined the HE staining of
tumor tissues and found that karyopyknosis and a
shape change were present in the tumor samples
treated with pCDNA-Loc554202, and these findings
were not noted in the negative control samples (Fig. 5e).
The tumors developed from pCDNA-Loc554202 cells dis-
played significantly increased cleaved caspase-3 staining
compared with tumors formed from empty vector trans-
fected cells (Fig. 5f). These results indicate that
Loc554202 is significantly associated with the proliferation
and apoptosis of colorectal cancer cells in vivo.
Fig. 2 Effects of Loc554202 overexpression on colorectal cancer cell proliferation in vitro. a A MTT assay was performed to determine the
proliferation of HCT116 and DLD1 cells following treatment with pCDNA-Loc554202 or empty vector. The data represent the means ± S.D. from
three independent experiments. b Colony-forming growth assays were performed to determine the proliferation of HCT116 and DLD1 cells. The
colonies were counted and captured. * P < 0.05 and ** P < 0.01
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Loc554202 promotes the apoptosis of colorectal cancer
cells via the caspase cleavage cascades
Various mechanisms have been studied to explain
lncRNA-mediated cell apoptosis, and the most important
pathway identified is the activation of specific caspase
cleavage cascades. To confirm the role of caspase activa-
tion in Loc554202 induced apoptosis, we treated HCT116
and DLD1 cells with a general caspase inhibitor, Z-VAD-
Fig. 3 Effects of Loc554202 on the cell cycle and apoptosis of colorectal cancer cells in vitro. HCT116 and DLD1 cells were transfected with
pCDNA-Loc554202 or empty vector. a and b The bar chart represents the percentage of cells in the G0/G1, S, or G2/M phases, as indicated. c and
d The percentage of apoptotic cells was determined by a flowcytometric analysis. The data represent the means ± S.D. from three independent
experiments. e The level of apoptosis in HCT116 and DLD1 cells after they were transfected with pCDNA-Loc554202 or empty vector as determined
by TUNEL staining.*P < 0.05
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Fig. 4 Effects of Loc554202 knockdown on colorectal cancer cell proliferation in vitro. a A MTT assay was performed to determine the proliferation of
HCT116 and DLD1 cells following transfection with si-Loc554202 or si-NC. The data represent the means ± S.D. from three independent experiments.
b Colony-forming growth assays were performed to determine the proliferation of HCT116 and DLD1 cells. The colonies were counted and captured.
* P < 0.05 and ** P < 0.01
Fig. 5 Loc554202 inhibits tumor growth in a xenograft mouse model. a The total numbers of tumors after removal from the mice. b The tumor
weights after the tumors were harvested. The data represent the means ± SD. ** P < 0.01. c The tumor volumes were calculated every three days
after inoculation. d qRT-PCR analyses indicated that the Loc554202 expression was significantly increased in vivo. e Representative images of HE
staining and immunohistochemical staining of the tumor. IHC showed an upregulation of the apoptosis index and cleaved caspase-3
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FMK (10 mmol/L). As shown in Fig. 6a, the pretreatment
with Z-VAD-FMK decreased the Loc554202 induced
apoptosis rate detected by flow cytometry. Consistent with
this finding, the results of a qRT-PCR analysis and western
blot analysis showed that the mRNA levels of Bax,
caspase-3 and caspase-9 and the protein levels of Bax,
cleaved caspase-3, cleaved caspase-9 were significantly
increased in pCDNA-Loc554202 treated cells, whereas the
mRNA and protein levels of Bcl-2 were decreased (Fig. 6b
and c). These findings indicate that Loc554202 induces
CRC cell apoptosis at least partly through the activation of
specific caspase cleavage cascades.
Fig. 6 Loc554202 promotes the apoptosis of colorectal cancer cells via the caspase cleavage cascades. a HCT116 and DLD1 cells were transfected with
pCDNA-Loc554202 in the presence or absence of Z-VAD-FMK (10 mmol/L) for 24 h. The apoptotic status of the cells was determined by a flowcytometric
analysis. The data represent the means ± SD. * P< 0.05. b The results of the qRT-PCR analysis of caspase-3, caspase-9, Bax, and Bcl-2 after the transfection of
pCDNA-Loc554202 or empty vector into HCT116 and DLD1 cells. c The results of the western blot analysis of the levels of cleaved caspase-3, cleaved
caspase-9, Bax and Bcl-2 after the transfection of pCDNA-Loc554202 or empty vector into HCT116 and DLD1 cells. The GAPDH protein was used as an
internal control. *P < 0.05
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Discussion
Over the past few decades, accumulating evidence has
shown that long non-coding RNAs (lncRNAs) play an
important role in the pathogenesis of cancer [6, 25, 26],
and can provide a novel platform for the diagnosis and
treatment of this disease. With the advances in tiling array
and novel sequencing technologies, it has been revealed
that only 2 % of the total human genome sequences en-
code proteins, whereas the remainder can be divided into
two groups according length, including short ncRNAs
(<200 nt) and long ncRNAs (>200 nt) [27, 28]. The
lncRNAs are important new members of the ncRNA fam-
ily, which are greater than 200 nt in length and can be
transcribed by RNA polymerase II (RNA pol II). Recent,
evidence has indicated that many lncRNAs can be consid-
ered as vital regulators of tumorigenesis [29, 30], as were
lncRNA SPRY4-IT1 [21] and HOTAIR [20] in our previ-
ous studies. Therefore, the identification of cancer-
associated lncRNAs and investigation of their molecular
and biological functions are important to provide new in-
sights into the diagnosis and treatment of cancer, includ-
ing colorectal cancer.
A previous study demonstrated that Loc554202 as
the host gene of miR-31 regulates the proliferation
and migration of breast cancer cells [22], and CpG is-
land methylation plays an important role in silencing
the Loc554202 genes [23]. However, the functions of
Loc554202 in CRC were previously unknown. In this
study, we provided the first evidence that lncRNA
Loc554202 was significantly downregulated in colorec-
tal cancer tissues compared with adjacent normal tis-
sues, and low expression of the lncRNA in CRC
patients was associated with an increased tumor size
and advanced TNM stage. The expression level of
miR-31 was no significant change after transfecting
CRC cells with pCDNA-Loc554202, which eliminated
the influence of miR-31 may exist on overexpression
of Loc554202. Additionally, DNA methylation could
restrain the expression of Loc554202. Our subsequent
studies showed that overexpression of Loc554202 de-
creased cell proliferation and caused a dramatic de-
crease in colony formation in the HCT116 and DLD1
cells. This result was confirmed by knocking down
Loc554202 in both CRC cell lines. These findings
suggest that Loc554202 might be a novel clinical
marker for the prognosis of CRC and might represent
a target for therapy.
To further clarify the functions of Loc554202 in CRC,
such as whether its expression influenced cell cycle
progression and apoptosis, we next used a flow cytometry
assay to detect the cell cycle progression and apoptosis in
HCT116 and DLD1cells after treatment with pCDNA-
Loc554202 or an empty vector. The results demonstrated
that Loc554202 overexpression promoted significant
arrest in the G0/G1-phase and an obvious increase in
apoptosis. These observations were verified by means of
TUNEL staining, immunohistochemical (IHC) assays and
in a mouse xenograft model. We also found that silencing
Loc554202 expression mildly inhibited apoptosis in
HCT116 and DLD1 cells in vitro. These results revealed
that the anti-proliferative effects of Loc554202 in the CRC
cells were mediated by its inhibition of cell cycle progres-
sion and induction of apoptosis.
Although lncRNAs have been shown to have vital bio-
logical functions in various malignant tumors, their precise
regulatory mechanisms remain largely unknown, although
many studies have focused on lncRNA-mediated effects on
cell apoptosis. For instance, lncRNA MEG3 inhibits non-
small cell lung cancer (NSCLC) cell proliferation and
induces apoptosis by affecting p53 expression [31], and
lncRNA ANRIL promotes NSCLC cell proliferation and
inhibits apoptosis by silencing KLF2 and P21 expression
[32]. However, the most important pathway discovered so
far is the activation of specific caspase cleavage cascades.
To further confirm the role of caspase activation in
Loc554202 induced apoptosis, we found that pretreat-
ment of cells with the pan-caspase inhibitor, Z-VAD-
FMK, decreased the Loc554202 induced apoptosis rate,
as detected by flow cytometry. Likewise, the outcomes of
qRT-PCR and western blot analyses showed that the
mRNA and the protein levels of the pro-apoptotic pro-
teins were significantly increased in pCDNA-Loc554202
treated cells, whereas the anti-apoptotic protein was de-
creased. These data indicate that Loc554202 induces
CRC cell apoptosis at least partly through the activation
of specific caspase cleavage cascades.
In summary, we have shown that Loc554202 is
downregulated in colorectal cancer tissues, and we
provided the first evidence that Loc554202 exerts crit-
ical effects on CRC cells by affecting both the cell
cycle and apoptosis. In addition, CpG island methyla-
tion plays an important role in silencing the
Loc554202 gene. Finally, we showed that Loc554202
regulated cell apoptosis at least partly through the
activation of specific caspase cleavage cascades. To-
gether, our findings suggest that lncRNA Loc554202 acts
as a tumor-inhibiting factor in CRC, and could be a candi-
date prognostic biomarker or a target for new cancer ther-
apies. However, further studies in a larger number of
samples and investigations of the other possible mecha-
nisms of action are required.
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